Apollomics Inc. (APLM)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Apollomics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | 20.62 | 20.84 | 20.60 | 20.84 | 4,865 |
| Oct 30, 2026 | 20.72 | 20.95 | 20.20 | 20.69 | 36,576 |
| Oct 29, 2026 | 19.54 | 22.74 | 19.51 | 20.80 | 63,251 |
| Oct 28, 2026 | 20.15 | 20.40 | 19.62 | 19.97 | 26,830 |
| Oct 27, 2026 | 19.98 | 21.30 | 19.07 | 19.85 | 486 |
| Oct 26, 2026 | 21.67 | 22.67 | 19.88 | 19.90 | 91,520 |
| Oct 23, 2026 | 22.84 | 23.07 | 20.95 | 21.84 | 7,160 |
| Oct 22, 2026 | 21.40 | 23.40 | 21.40 | 22.00 | 3,165 |
| Oct 21, 2026 | 21.66 | 21.76 | 21.51 | 21.59 | 3,250 |
| Oct 20, 2026 | 21.80 | 23.75 | 21.10 | 21.66 | 409 |
| Oct 19, 2026 | 21.00 | 22.70 | 21.00 | 22.05 | 5,459 |
| Oct 16, 2026 | 21.10 | 21.28 | 21.00 | 21.10 | 6,232 |
| Oct 15, 2026 | 21.81 | 22.62 | 21.00 | 21.00 | 7,438 |
| Oct 14, 2026 | 21.77 | 21.77 | 21.77 | 21.77 | 2,046 |
| Oct 13, 2026 | 21.18 | 22.76 | 21.00 | 21.70 | 493 |
| Oct 12, 2026 | 21.17 | 21.32 | 21.17 | 21.32 | 1,743 |
| Oct 9, 2026 | 21.70 | 22.50 | 21.10 | 21.50 | 8,793 |
| Oct 8, 2026 | 22.65 | 22.65 | 21.25 | 21.78 | 6,602 |
| Oct 7, 2026 | 21.95 | 22.25 | 21.50 | 21.50 | 6,622 |
| Oct 6, 2026 | 23.70 | 23.70 | 21.90 | 22.10 | 13,177 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 CHEN HONG-JUNG | Director | Option Exercise | 500 | -- | Sep 15, 2026 |
 Yen Hung Hsien | Director | Option Exercise | 500 | -- | Sep 15, 2026 |
 LIN PETER KUAN-HOW | Chief Financial Officer | Option Exercise | 10.0K | -- | Sep 15, 2026 |
 Chen Yi-Kuei | Chief Operating Officer | Option Exercise | 5.0K | -- | Sep 15, 2026 |
 Chen Hung-Wen | Chief Executive Officer | Option Exercise | 5.0K | -- | Sep 15, 2026 |
 TSAI HSIEN-SHU | Director | Option Exercise | 500 | -- | Sep 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Hung-Wen Chen · may incl. warrants· filed Sep 2025 | 896.4K | 30.8% | 13D |
HRT FINANCIAL LP APLMW | 594.0K | -- | 13F |
Clear Street Group Inc. APLMW | 505.9K | -- | 13F |
BOOTHBAY FUND MANAGEMENT, LLC APLMW | 373.7K | -- | 13F |
D. E. Shaw & Co., Inc. APLMW | 318.5K | -- | 13F |
Context Capital Management, LLC APLMW | 298.5K | -- | 13F |
MMCAP International Inc. SPC APLMW | 250.0K | -- | 13F |
683 Capital Management, LLC APLMW | 130.0K | -- | 13F |
WOLVERINE ASSET MANAGEMENT LLC APLMW | 129.4K | -- | 13F |
Maxpro Investment Co., Ltd · filed Sep 2025 | 101.2K+3.8K via warrants | 3.6% | 13G |
Insiders
- CHEN HONG-JUNGDirector
- Yen Hung HsienDirector
- LIN PETER KUAN-HOWChief Financial Officer
- Chen Yi-KueiChief Operating Officer
- Chen Hung-WenChief Executive Officer
- TSAI HSIEN-SHUDirector
- Huang Ya-ChiDirector
- Jan Chen-HuanDirector
- CHU YI-ANDirector
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia.
The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements.
Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
based on 2.91M shares outstanding
US30d Avg
14.81K
60d Avg
13.19K
90d Avg
11.79K